Fulgent Genetics, Inc. (FLGT) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

63OpportunityDD: Aug 06, 2026Analyst: 67

paidPrice at analysis date

USD 18.5 (06/08/2026)

domainMkt cap

$295.26M

pie_chartShares

candlestick_chart52W

2026-08

trending_downShort interest

15.2%

INFONASDAQHealth Care1315 employeesFounded 2011

Verdict: Favorable Risk/Reward

FLGT is a cash-backed diagnostics turnaround with an early oncology option. The stock trades near or below a conservative liquid-asset floor when the expected IRS refund is included, while the market assigns limited value to the lab platform, Bako/StrataDx integration and FID-007 optionality. The thesis is not clean: billing delays, negative EBITDA and legal-governance noise keep the discount justified until execution improves.

DIANALITICS RESEARCH INDEX

Score /100 - updated 2026-08-06

Fulgent Genetics (FLGT)

Diagnostics services, digital pathology and oncology therapeutics

Cash floor is real; operating losses and reimbursement execution decide whether the market gives the lab business any credit.

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

Net cash screen Buyback active Billing remediation risk Negative EBITDA

Fair value base case

USD 30.0

Range: USD 15.0-USD 42.0

Price at analysis date: USD 18.5 (06/08/2026)

Base upside/downside: +62%

Implied operating EV is about $268M, equal to 0.80x FY2026 guided revenue midpoint. A second-method check using refund-adjusted net liquid assets plus 0.6x lab revenue gives about $27.60 per share, within 8% of base FV. A +/-0.2x EV/revenue sensitivity moves FV by roughly +/-$2.44 per share. Not investment advice.

Component	Assumption	USD/share
Net liquid asset floor	($551.5M cash + securities - $93.2M liabilities) / 27.52M shares	+16.65
IRS refund receivable	85% probability x $106.1M anticipated tax refund / 27.52M shares	+3.28
Lab services EV	$335M FY2026 revenue guide midpoint x 0.80x EV/Revenue / 27.52M shares	+9.74
FID-007 / FID-022 option	15% probability x $200M oncology platform value / 27.52M shares	+1.09
Billing and integration reserve	-$12.4M explicit reserve for RCM remediation and Bako/StrataDx integration / 27.52M shares	-0.45
SBC / litigation reserve	-$8.3M reserve for stock comp drag and law-firm investigation overhang / 27.52M shares	-0.30
FV base case	16.65 + 3.28 + 9.74 + 1.09 - 0.45 - 0.30 = $30.01, rounded	30.00

Bull

$38 - $42

Probability: 20%

Tax refund arrives in 2026, Bako/StrataDx lift collections, lab revenue reaccelerates and FID-007 Phase 3 design becomes credible.

Base

$28 - $32

Probability: 45%

Guidance is delivered, cash burn slows and the market assigns a discounted 0.8x EV/revenue to the lab platform.

Bear

$14 - $17

Probability: 35%

Refund is delayed, billing drag persists, adjusted EBITDA losses consume cash and the therapeutics option receives little credit.

Methodology: Implied operating EV is about $268M, equal to 0.80x FY2026 guided revenue midpoint. A second-method check using refund-adjusted net liquid assets plus 0.6x lab revenue gives about $27.60 per share, within 8% of base FV. A +/-0.2x EV/revenue sensitivity moves FV by roughly +/-$2.44 per share. Not investment advice. Not investment advice.

check_circle

Asset-backed dislocation with a dated catalyst path

The selection screen classified FLGT as a NET_CASH / CATALYST dislocation. Conservative net liquid assets excluding the delayed tax refund are about $16.65 per share, while refund-adjusted liquid value is about $20.51 per share versus a $18.53 close on 2026-08-05. The rerating path depends on 2026 billing remediation, Bako/StrataDx integration and Phase 3 planning for FID-007 after ASCO 2026 data.

Methodology note: The dislocation label and asymmetry ratio are only screening criteria. The fair value below is built independently from observed cash, reported liabilities, FY2026 revenue guidance, peer multiples and explicit risk reserves.

Capital Structure - Short Interest - Buyback & Dilution

Short Interest

15.2%

2.75M shares short as of 2026-07-15, about 11.4 days to cover. The setup can amplify a positive billing or refund update, but it also signals real skepticism.

Share dilution (1Y)

-3.1%

Weighted shares fell from 30.54M in Q2 2025 to 28.01M in Q2 2026; StockAnalysis still shows current shares up 0.95% YoY due timing/classification.

Buyback

$63.9M YTD

Management repurchased about 4.1M shares through 2026-06-30, including $23.8M in Q2. No further repurchases are assumed in FY2026 cash guidance.

Short Interest - context

FLGT - 15.2%

15.2%

Insider/governance check: Fulgent IR shows multiple Form 4 filings and one Form 144 filing in late May / early June 2026. The accessible snippets confirm filings but not a single named open-market sale above $500K; the report therefore treats insider activity as an overhang, not as quantified selling evidence.

$Financial analysis - FY 2023-2026E

Q2 revenue

$85.4M

+20.1% sequentially, but guidance cut

Q2 gross margin

30.1%

Down from 42.1% in Q2 2025

Liquidity

$551.5M

Excludes expected $106.1M tax refund

FY2026 guide

$330-340M

Revenue guidance revised lower

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2026
Revenue	$289.2M	$283.5M	$322.7M	$335.0M	$330-340M official guide
Gross margin	36.1%	37.8%	40.6% non-GAAP	~32-34% est.	Needs collection normalization
Adjusted EBITDA / core EBITDA	-$9.2M core	-$19.0M core	N/D - metric retired	negative	Non-GAAP loss $63-67M
Net loss attributable to FLGT	-$167.8M	-$42.7M	N/D in report table	~-$100M run-rate risk	Loss remains material
Cash, restricted cash and marketable securities	N/D	N/D	$705.5M	~$610.0M year-end guide	Includes tax refund assumption

Q2 2026 was better sequentially on revenue, but the investment case is still balance-sheet-led because gross margin and non-GAAP loss deteriorated year over year.

Quarterly dynamics - last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue ($M)	81.8	84.0	83.3	71.1	85.4
Gross margin %	42.1%	N/D	39.1%	30.2%	30.1%
Net loss ($M)	-19.0	N/D	-23.4	-24.8	-29.5
Cash + investments EOP ($M)	N/D	N/D	705.5	604.7	551.5

Financial position and sustainability

Refund-adjusted floor

$20.51/sh

Q2 gross margin

30.1%

Short float

15.2%

article

Business model - cash-backed lab platform plus oncology option

What the market is discounting

Fulgent has moved from a COVID-era diagnostics windfall into a broader lab services business with anatomic pathology, dermatopathology, molecular diagnostics and a small therapeutic development arm. The Bako and StrataDx assets expand commercial reach and test menu depth, but the Q2 guide cut shows that revenue cycle management and collection mechanics matter more than headline volume. The oncology pipeline is relevant but should be treated as option value until pivotal design, funding and regulatory clarity improve.

Core lab services ~$260-275M FY2026E (80%+ rev) cash generative potential Genetic and molecular testing remain the base platform. The main lever is reimbursement discipline: if collections normalize, the market can value the business on revenue rather than only cash. Bako / StrataDx pathology ~$55-70M FY2026E contribution integration test The March 2026 acquisition adds dermatopathology, podiatric pathology and molecular diagnostics. Synergy depends on AI pathology workflow adoption and salesforce cross-selling. Therapeutic development minimal revenue; $26M FY2026 spend plan binary option FID-007 has encouraging Phase 2 HNSCC data, but commercialization value requires Phase 3 execution and capital allocation discipline.

article

Legal, regulatory and risk analysis

Billing and collections

High

Management cut FY2026 revenue guidance due to processing delays from the final phase of the revenue-cycle and billing-system transition. If collections do not normalize, the lab EV component should be reduced sharply.

Cash floor protection

Positive

Cash, restricted cash and marketable securities were $551.5M at Q2 close, before an expected $106.1M tax refund. That balance anchors downside better than a pure going-concern story.

Adjusted EBITDA losses

High

Q2 adjusted EBITDA loss was $17.1M and FY2026 non-GAAP loss guidance is $63-67M. The floor erodes if the cash burn remains at this cadence.

Tax refund timing

Moderate

Management assumes receipt of about $106.1M before year-end 2026. A delay does not break the company, but it lowers the hard-floor calculation from about $20.51 to $16.65 per share.

FID-007 clinical risk

Moderate

ASCO 2026 data showed encouraging activity and manageable safety, but the dataset is Phase 2. Phase 3 design, comparator, enrollment and financing remain value-critical.

Short interest

Moderate

Short float above 15% can create squeeze risk on good news, but it also indicates investor concern about collection quality, margin pressure and capital allocation.

Governance / law-firm noise

Moderate

Law-firm investigation headlines appeared after the spring 2026 clinical/news flow, and SEC filing snippets show recent Form 4/144 activity. No SEC enforcement action was verified in accessible sources.

Buyback discipline

Positive

Repurchasing 4.1M shares through June 2026 below refund-adjusted cash value is economically sensible if liquidity stays above plan and operating losses narrow.

article

SWOT analysis

Strengths

+Large liquid balance sheet relative to market cap.
+Active repurchase program reduces share count at discounted prices.
+Expanded pathology footprint through Bako and StrataDx.
+FID-007 provides upside that is not needed to justify the entire base case.

Weaknesses

−Negative adjusted EBITDA and non-GAAP losses.
−Gross margin compressed sharply versus Q2 2025.
−FY2026 guidance cut damages near-term credibility.
−Therapeutic development spend competes with buybacks and M&A.

Opportunities

→IRS refund receipt can make the cash floor more visible.
→RCM remediation can unlock a lab services re-rating.
→AI pathology integration can improve Bako/StrataDx throughput.
→Phase 3 planning for FID-007 can raise option value.

Threats

!Further collection delays reduce revenue quality.
!Cash burn can consume the perceived margin of safety.
!Clinical/regulatory setbacks can eliminate the oncology option.
!Legal or insider-selling headlines can keep the discount persistent.

article

Summary by assessment area

Balance sheet - favorable

Refund-adjusted liquid value is above the T-1 share price.
No meaningful operating debt burden appears in Q2 data.

Operations - watch closely

Revenue rebounded sequentially, but margin and guidance quality are weak.
Bako/StrataDx must prove contribution without persistent integration drag.

Catalysts - valuation aware

Refund receipt and Q3/Q4 collection updates are the nearest re-rating events.
FID-007 Phase 3 clarity can add upside, but should stay option value.

Sources & Disclaimer

Sources: Price/market data - Yahoo Finance chart API and CNBC quote cache, last verified close 2026-08-05 at $18.53; market cap, shares and 52W range - CNBC quote cache on 2026-08-06 ($509.9M market cap, 27.52M shares, 52W $13.46-$31.04) and StockAnalysis history/statistics cross-check through 2026-07-30. Official results / IR filings - Fulgent Q2 2026 results press release dated 2026-07-30 and Q1/Q2 SEC filing links from Fulgent IR / SEC. Historical financials - Fulgent FY2025 10-K, Q2 2026 release and StockAnalysis revenue/financials pages. Short interest - MarketBeat short interest page, record date 2026-07-15. Analyst target - MarketBeat forecast page refreshed 2026-07-27 and Investing.com analyst ratings table showing Piper Sandler $15 target dated 2026-05-05. Governance / insider / class-action check - Fulgent IR SEC filings page showing Form 4/Form 144 filings in late May / early June 2026, StockAnalysis news links to law-firm investigations, and FY2025 10-K legal proceedings disclosure; no SEC enforcement action verified from accessible sources. Peer comparables - DGX, LH, NEO, CDNA from StockAnalysis/Yahoo/CNBC valuation statistics. Market data - last verified close 2026-08-05. This document is for informational purposes only and does not constitute financial or investment advice.